Trade INTS anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Intensity Therapeutics, Inc. (INTS) is trading at US$4.39, up 2.76% today as of Aug 28, 12:00 EDT. The company has a market capitalisation of US$15.87M. Over the past 52 weeks, INTS has traded between US$3.51 and US$43.50. On Syfe you can trade INTS with $0 commission and add it to your watchlist.
| Previous close | US$4.27 |
|---|---|
| Market cap | US$15.87M |
| 52-week range | US$3.51 – US$43.50 |
| Volume | 75.2K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.
Year: 2023
Intensity Therapeutics Resumes Dosing in Phase 2 Trial for Investigational Cancer Therapy in Switzerland
Jul 15, 12:15 PM · MT Newswires
Intensity Therapeutics, Inc. (INTS) stock is trading at US$4.39, +2.76% from the previous close of US$4.27.
The market cap for Intensity Therapeutics, Inc. (INTS) stock is approximately US$15.87M.
The 52-week high for Intensity Therapeutics, Inc. (INTS) stock is US$43.50.
The 52-week low for Intensity Therapeutics, Inc. (INTS) stock is US$3.51.
Intensity Therapeutics, Inc. (INTS) does not currently pay a dividend.
Stay on top of INTS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
